As the number of opioid-related deaths continues to rise across Canada, new federal legislation is aimed at reducing the number of deaths from overdoses.
The World Health Organization (WHO) is to launch a pilot project this year to evaluate inexpensive copies of costly drugs for biotechnology cancer to make these drugs more accessible in the poorest countries.
The US House of Representatives, controlled by the Republicans, passed a new version of the American Health Care Act to repeal and replace Obamacare, by a vote of 217 to 213. The Republican leaders of the house have blurred to gain sufficient support for the vote after adding a series of changes since an earlier version was taken from a vote in Parliament at the last minute of March.
Researchers have developed a custom algorithm that predicts the impact of certain foods on an individual's blood sugar, according to a new study published in PLOSComputational Biology.
Roche Diagnostics UK and Ireland launches the next generation of INR patient self-monitoring meter for patients on warfarin anticoagulant therapy. The new CoaguChek INRange meter allows patients to send their results to their clinic via an App on their phone using wireless connectivity.
Takeda Pharmaceutical Company Limited announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ALUNBRIG, which previously received Breakthrough Therapy Designation from the FDA, is a once-daily oral therapy that may be taken with or without food.
The Indian Council of Medical Research (ICMR) has launched "The Indian Rare Disease Registry" to meet the unmet needs of patients with rare diseases and to help the country develop data and information to support research and Development and improve innovation.
A growing number of healthcare institutions and the growing demand for modernization of health care, according to experts, have made it even more important to set up a robust computer system by the Indian health accessible and affordable.
The National Pharmaceutical Pricing Authority (NPPA) has set price caps for an additional 15 drugs, including those used for the treatment of heart disease, infections, cancer, hypertension and pain relief.
ProQR Therapeutics N.V. announced that the Company can start the Phase 1/2 trial for QR-110, named PQ-110-001, in Leber’s congenital amaurosis Type 10 (LCA 10) patients. QR-110 is a novel investigational RNA therapeutic targeting LCA 10 due to the p.Cys998X mutation, a severe genetic rare disease that causes children to lose sight in the first years of life. LCA 10 is one of the most prevalent forms of gene-related blindness in children worldwide and currently there are no therapies commercially available.